Pdb33 Cost Comparison of Insulin Glargine and Insulin Detemir in Type 2 Diabetes Mellitus in Argentina: A Trial-Based Probabilistic Model

Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany

“…The results of our cost analysis comparing the direct treatment costs between the two regimes showed lower annual costs per patient for Germany in favour of insulin glargine. The results of this cost comparison are consistent with the findings of further recent German cost comparisons between insulin glargine and insulin detemir such as the Rosenstock RCT [ 3 ], the LIVE-COM study [ 17 ], the LIVE-KK study [ 23 ] and findings from other countries [ 4 ], [ 5 ], [ 6 ], [ 7 ], [ 8 ].…”

“…Nonetheless, both trial based cost comparisons for insulin glargine and insulin detemir [ 3 ], [ 4 ], [ 5 ], [ 6 ], [ 7 ], [ 8 ] as well as comparisons based on “real-life” data [ 23 ], [ 24 ], [ 28 ] have consistently reported a cost-advantage for glargine based regimes. Moreover, clinical trials designed to specifically show non-inferiority with the comparator insulin, may not show the true value of glargine in real-life use than detemir [ 25 ].…”

“…An earlier cost analysis comparing basal insulin analogues glargine versus detemir in combination with oral antidiabetic drugs (basal supported oral therapy; BOT) in insulin naive T2D patients in Germany based on the findings of the Rosenstock trial [ 2 ] has been conducted from the perspective of the statutory health insurance (SHI) in Germany [ 3 ] and other countries [ 4 ], [ 5 ], [ 6 ], [ 7 ], [ 8 ]. Since transferability from one country to another is usually restricted, country-specific evaluations are required that take into account country-specific features such as epidemiology of diabetes, treatment guidelines, patterns of health service (resource) use, unit costs and reimbursement regulations [ 9 ].…”